MEDI-528, now recognized as enokiizumab , represents a novel therapeutic targeting the IGF1R, a vital protein involved in various skin conditions . Early investigation results suggest significant https://janacuoa633909.wikicorrespondence.com/6764302/enokizumab_a_deep_dive_into_medi_528_and_its_potential